Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors

Oncologist

Volumn 13, Issue 4, 2008, Pages 459-466

  Tawbi, Hussein ^a   Thomas, Dafydd ^b   Lucas, David R ^b   Biermann, J Sybil ^c   Schuetze, Scott M ^b   Hart, Anita L ^b   Chugh, Rashmi ^b   Baker, Laurence H ^b,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Division of Hematology Oncology 3216 Cancer Center   (United States)

Author keywords

EGFR mutation analysis; Immunohistochemistry; Malignant peripheral nerve sheath tumor; Synovial sarcoma

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DNA ISOLATION; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NERVE SHEATH TUMOR; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SURVIVAL RATE; SYNOVIAL SARCOMA; TISSUE MICROARRAY; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NERVE SHEATH NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; SARCOMA, SYNOVIAL; TRANSLOCATION, GENETIC;

EID: 43549101707     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0166     Document Type: Article

References (38)

1. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors, Fourth Edition. St. Louis: Mosby, Inc., 2001:1-1622.
2. Francis P, Namlos HM, Muller C et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: Hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007;8:73.
3. Baird K, Davis S, Antonescu CR et al. Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res 2005;65:9226-9235.
4. Brennan MF, Casper ES, Harrison LB. Soft tissue sarcoma. In: DeVita VT Jr, Hellman S, Rosenberg SA et al., eds. Cancer: Principles and Practice of Oncology, Fifth Edition. Philadelphia: Lippincott-Raven, 1997:1738-1852.
5. Kawai A, Woodruff J, Healey JH et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153-160.
6. Inagaki H, Nagasaka T, Otsuka T et al. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 2000;13:482-488.
7. Ducatman BS, Scheithauer BW, Piepgras DG et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-2021.
8. Wong WW, Hirose T, Scheithauer BW et al. Malignant peripheral nerve sheath tumor: Analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998;42:351-360.
9. Hruban RH, Shiu MH, Senie RT et al. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer 1990;66:1253-1265.
10. Kourea HP, Bilsky MH, Leung DH et al. Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: A clinicopathologic study of 25 patients and 26 tumors. Cancer 1998;82:2191-2203.
11. Carli M, Ferrari A, Mattke A et al. Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 2005;23:8422-8430.
12. Ghosh BC, Ghosh L, Huvos AG et al. Malignant schwannoma. A clinico-pathologic study. Cancer 1973;31:184-190.
13. Wanebo JE, Malik JM, VandenBerg SR et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer 1993;71:1247-1253.
14. Ferrari A, Bisogno G, Macaluso A et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 2007;109:1406-1412.
15. Thomas DG, Giordano TJ, Sanders D et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005;103:830-838.
16. Yarden Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(suppl 4):S3-S8.
17. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
18. Rosell R, Taron M, Reguart N et al. Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006;12:7222-7231.
19. Fletcher CDM, Unni KK, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press, 2002:1-427.
20. Nocito A, Kononen J, Kallioniemi OP et al. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001;94:1-5.
21. Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 2006;19:659-668.
22. Wang S, Saboorian MH, Frenkel E et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-381.
23. Yantiss RK, Rosenberg AE, Sarran L et al. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: A pathologic and molecular study. Mod Pathol 2005;18:475-484.
24. Nicholas MK, Lukas RV, Jafri NF et al. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006;12:7261-7270.
25. Ji H, Zhao X, Yuza Y et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2006;103:7817-7822.
26. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
27. Basu TN, Gutmann DH, Fletcher JA et al. Aberrant regulation of Ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-715.
28. DeClue JE, Heffelfinger S, Benvenuto G et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000;105:1233-1241.
29. Li H, Velasco-Miguel S, Vass WC et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 2002;62:4507-4513.
30. Perry A, Kunz SN, Fuller CE et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002;61:702-709.
31. Ling BC, Wu J, Miller SJ et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005;7:65-75.
32. Mahller YY, Vaikunth SS, Currier MA et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 2007;15:279-286.
33. Albritton KH, Rankin C, Coffin CM, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol 2006;24(18 suppl):524s.
34. Gusterson B, Cowley G, McIlhinney J et al. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer 1985;36:689-693.
35. Barbashina V, Benevenia J, Aviv H et al. Oncoproteins and proliferation markers in synovial sarcomas: A clinicopathologic study of 19 cases. J Cancer Res Clin Oncol 2002;128:610-616.
36. Bode B, Frigerio S, Behnke S et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006;19:541-547.
37. Terry J, Lubieniecka JM, Kwan W et al. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 2005;11:5631-5638.
38. Blay J, Le Cesne A, Whelan J et al. Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2006;24(18 suppl):524s.